Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. LabTurbo Biotech's Marketable Securities for the quarter that ended in Jun. 2026 was NT$643.28 Mil.
LabTurbo Biotech's annual Marketable Securities
increased
from Dec. 2023 (NT$559.30 Mil) to Dec. 2024 (NT$710.83 Mil) but then
declined
from Dec. 2024 (NT$710.83 Mil) to Dec. 2025 (NT$488.62 Mil).
Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.
Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".
LabTurbo Biotech Marketable Securities Related Terms
LabTurbo Biotech Marketable Securities Historical Data
* Premium members only.
The historical data trend for LabTurbo Biotech's Marketable Securities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Marketable Securities of NT$643.28 Mil mean?
LabTurbo Biotech (ROCO:7725) has a Marketable Securities of NT$643.28 Mil as of Jun. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on LabTurbo Biotech and its competitors.
Is LabTurbo Biotech's Marketable Securities too high?
LabTurbo Biotech's current Marketable Securities is NT$643.28 Mil. Overall, LabTurbo Biotech has a GF Score™ of 36/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does LabTurbo Biotech's Marketable Securities compare to VRTX and REGN?
LabTurbo Biotech's Marketable Securities of NT$643.28 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on LabTurbo Biotech and its competitors. LabTurbo Biotech's current Marketable Securities is NT$643.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LabTurbo Biotech stock overvalued right now?
Based on GuruFocus' analysis, LabTurbo Biotech (ROCO:7725) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$28.30, compared to a current price of NT$23.15 — trading 18.2% below its estimated fair value. The current Marketable Securities is NT$643.28 Mil. LabTurbo Biotech's overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For LabTurbo Biotech (ROCO:7725), the current Marketable Securities is NT$643.28 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LabTurbo Biotech (ROCO:7725) Overvalued in 2026?
Based on GuruFocus' analysis, LabTurbo Biotech stock appears to be undervalued.
The current stock price of NT$23.15 is trading 18.2% below its estimated GF Value™ of NT$28.30.
GuruFocus considers LabTurbo Biotech to be Modestly Undervalued.
Key valuation signals for ROCO:7725:
Marketable Securities: NT$643.28 Mil
GF Value™: NT$28.30 vs. price of NT$23.15 (18.2% below fair value)
No single metric tells the full story. See the ROCO:7725 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LabTurbo Biotech Corp is a company that is mainly engaged in the research and development, production, sales of nucleic acid extraction, genetic testing, genetic testing reagents, instruments, and the operation of sports science venues. Its main products and services include the entire process. Automated precision medical genetic testing systems and reagent kits as well as testing services.
36GF Score
Get the complete analysis for ROCO:7725
Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7725 has been successfully added to your 
